Scientists have identified a protective brain pathway that may help slow the progression of Parkinson's disease by strengthening the brain's own dopamine‑producing neurons, but the positive effect was only observed in females.
In the Journal of Neuroscience , researchers report that enhancing a pathway involving nicotine‑responsive receptors helped preserve dopamine‑producing neurons and reduced signs of degeneration in female models. Crucially, the effect occurred by boosting nicotine-responsive receptors without using nicotine. The findings point to a possible way to slow Parkinson's itself, not just manage its symptoms, in a disease where progression has been impossible to stop.
"This work is about keeping neurons alive longer," said Dr. Rahul Srinivasan , associate professor of neuroscience at the Texas A&M University Naresh K. Vashisht College of Medicine . "If you can preserve dopamine‑producing cells, you have a real opportunity to slow the rate at which the disease advances."
Tobacco still bad for you
Understanding how the brain responds to nicotine has long attracted attention in Parkinson's research, but nicotine is addictive and affects many systems throughout the body, making it unsuitable for long‑term therapy. Instead, the new findings point to protective pathways directly affected by nicotine, without relying on this harmful substance.
"Despite the nicotine connection, these receptors exist to serve normal brain function," said Srinivasan, whose team includes Dr. Gauri Pandey, a Ph.D. graduate of the College of Medicine, and current M.D./Ph.D. student Roger Garcia. "Nicotine just hijacks a receptor system that's already there."
The pathway identified in the study centers on receptors that respond to acetylcholine, a natural brain chemical involved in movement and communication between neurons and the receptors where nicotine happens to bind.
Parkinson's disease worsens as dopamine‑producing neurons gradually die, and although current treatments can ease symptoms by replacing dopamine or mimicking its effects, they do not stop the underlying neuron loss that drives progression.
Earlier work from Srinivasan's lab showed that certain nicotine‑related drugs could protect dopamine‑producing neurons in female models. The new study asked whether activating those receptors was necessary, or whether the brain's own protective pathway could be strengthened without nicotine.
To answer that question, the researchers used gene editing to increase the availability of nicotine‑responsive receptors, ensuring more of them reached the parts of the neuron where they are needed, without exposing the brain to nicotine or nicotine‑like drugs.
The results showed that reinforcing this protective brain pathway helped dopamine‑producing neurons remain intact under conditions that normally cause degeneration, while surrounding brain cells showed reduced reactivity, signaling healthier neural tissue.
Why only females?
One of the team's most striking findings is that the protective brain mechanism operated only in female models. Across multiple measures — including preservation of dopamine neurons, reduced activation of cell‑death signals and healthier surrounding brain tissue — females consistently showed protection, while males did not.
"This wasn't a subtle difference," Srinivasan said. "The protective pathway was clearly engaged in females and absent in males."
Parkinson's disease affects males and females differently, and growing evidence suggests that biological sex plays a central role in how neurons respond to damage. Hormones, receptor trafficking and cellular regulation (the processes governing cell behavior) may all contribute to why the pathway functions differently across sexes.
"This study reinforces that sex differences are not secondary details, they are fundamental to how the disease works and how treatments may need to be designed," Srinivasan said.
Toward treatments that slow the disease itself
Because the newly identified pathway helps preserve dopamine‑producing neurons rather than simply compensating for their loss, the findings align with a broader push toward disease‑modifying Parkinson's therapies.
"Every additional year that these neurons remain functional matters," Srinivasan said. "If we can strengthen protective brain pathways early, we may be able to meaningfully slow Parkinson's progression and improve the quality of life of patients with Parkinson's."
While further research will be needed to determine how this pathway could be targeted in people, the study offers a clear takeaway: slowing Parkinson's disease may depend not just on treating symptoms, but on helping the brain protect what it can't afford to lose.
By Lesley Henton, Texas A&M University Division of Marketing and Communications
